GLP-1 Therapies Research Papers | Page 15 | OpenScience.ink

1 week ago • Diabetes, obesity, and cardiometabolic CARE

How Adults with Obesity Stop, Restart, or Change Injectable Semaglutide and Tirzepatide TreatmentsPatterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With Obesity.

Article

1 week ago • Cureus

Muscle and Bone Side Effects Linked to Semaglutide, Liraglutide, and Tirzepatide in FDA ReportsMusculoskeletal Adverse Event Signals Associated With Semaglutide, Liraglutide, and Tirzepatide in the US FDA Adverse Event Reporting System.

Article

1 week ago • Diabetes, obesity & metabolism

How Accurately Is Nausea Measured in Obesity Trials Using GLP-1 Treatments?How Well Are We Measuring Nausea? A Narrative Review of Patient-Reported Outcome Gaps in GLP-1 Receptor Agonist Obesity Trials.

Article

1 week ago • JAMA

Patterns of Dispensing Combined GLP-1 Treatments with Vitamin B12Compounded GLP-1 Dispensing Patterns and Vitamin B12 Coformulation.

Article

1 week ago • Cureus

Onset and Progression of Diabetic Eye Disease During Treatment with Semaglutide or Tirzepatide, Including a Review of a Specific Type of Optic Nerve DamageDiabetic Retinal Disease Onset and Progression During Established Semaglutide or Tirzepatide Treatment: A Retrospective Comparative Cohort Study With a Descriptive Regional Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Review.

Article

1 week ago • Diabetes, obesity & metabolism

Long-Term Compared to Short-Term GLP-1 Receptor Agonist Use and Metabolic Health in Older Adults Without DiabetesSustained Versus Minimal GLP-1 Receptor Agonist Exposure and Metabolic Outcomes in Older Adults Without Diabetes.

Article

2 weeks ago • Epilepsia

How GLP-1 receptor drugs may change seizure risk depending on the situationBeyond neuroprotection: Context-dependent effects of GLP-1 receptor agonists on seizure susceptibility.

Article

2 weeks ago • Diabetes, obesity & metabolism

How Starting Semaglutide in Real Life in the US Affects Early Treatment Stopping and Staying on It for One YearReal-World Semaglutide Initiation Behaviours in the United States: Impact on Early Treatment Discontinuation and on 1-Year Persistence.

Article

2 weeks ago • Journal of controlled release : official journal of the Controlled Release Society

Comparing how different enhancers affect intestinal delivery of semaglutideMechanistic benchmarking of SNAC, DDM, and LLC reveals enhancer-dependent pathways for intestinal semaglutide delivery.

Article

2 weeks ago • Diabetes, obesity & metabolism

Weight regain after hormone treatment: possible link to low muscle mass and benefits of adding testosterone in menWeight Regain After Incretin Treatment: The Lean Mass Deficit Hypothesis and a Role for Testosterone Combination Therapy in Men.

Article

2 weeks ago • Journal of the American Society of Nephrology : JASN

Drugs that Activate Glucagon-Like Peptide-1 and Other Hormone Receptors for Protecting Kidneys in People Without DiabetesGlucagon-Like Peptide-1 Receptor Agonists and Multi-hormone Receptor Modulators for Kidney Protection in Nondiabetic Kidney Disease.

Article

2 weeks ago • Neurogastroenterology and motility

Gut Symptoms and Movement Changes Linked to GLP-1 Receptor AgonistsGastrointestinal Symptom Events and Motility Alterations Associated With GLP-1 Receptor Agonists.

Article

2 weeks ago • European journal of obstetrics, gynecology, and reproductive biology

Glucagon-like peptide-1 receptor agonists compared to metformin and their impact on pregnancy rates in women with polycystic ovary syndromeThe effect of glucagon-like peptide-1 receptor agonists versus metformin on pregnancy rates in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized trials.

Article

2 weeks ago • Cureus

Reducing Sleep Apnea Treatment After Weight Loss Caused by Diabetes MedicationDe-escalating Therapy in Obstructive Sleep Apnoea After Glucagon-Like Peptide-1 Receptor Agonist-Induced Weight Loss: A Narrative Review.

Article

2 weeks ago • Diabetes, obesity, and cardiometabolic CARE

Physical activity habits in adults using GLP-1 receptor drugsPhysical Activity Patterns in Adults Taking Glucagon-Like Peptide 1 Receptor Agonists: An All of Us Cross-sectional Study.

Article

2 weeks ago • International journal of cardiology

GLP-1 receptor agonist treatment and new cases of irregular heartbeat in non-diabetic adults with obesity and kidney diseaseGLP-1 receptor agonist therapy and incident atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease: a propensity matched cohort study.

Article

2 weeks ago • Diabetes, obesity, and cardiometabolic CARE

Changes in Diabetes Medicines After Metformin in Patients with High Compared to Moderate Heart Risk from 2014 to 2022Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate Cardiovascular Risk: The BESTMED Consortium 2014-2022.

Article

2 weeks ago • Diabetes, obesity, and cardiometabolic CARE

Who Among U.S. Women of Childbearing Age Can Use GLP-1 Receptor Agonist TreatmentsGLP-1 RA Eligibility in Reproductive-Age U.S. Women.

Article

2 weeks ago • Cureus

Effectiveness, Safety, and Future Use of Hormone-Based Drugs for Treating ObesityModern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists.

Article

2 weeks ago • Acta diabetologica

Use of GLP-1 receptor drugs and risk of kidney damage after contrast scans in adults with type 2 diabetes and chronic kidney diseaseGLP-1 receptor agonist use and contrast-associated acute kidney injury after contrast-enhanced CT and CT angiography in adults with type 2 diabetes and chronic kidney disease: a propensity score-matched cohort study.

Article

2 weeks ago • Progress in neuro-psychopharmacology & biological psychiatry

Using glucagon-like peptide-1 receptor activators to reduce brain inflammation and their possible treatment role in schizophreniaModulating neuroinflammation with glucagon-like peptide-1 receptor agonists: a scoping review exploring their therapeutic potential in schizophrenia.

Article

2 weeks ago • Current medical research and opinion

Improved care and treatment results for obesity and knee arthritis in primary careAdvances in disease management and treatment outcomes for obesity and knee osteoarthritis in primary care practice.

Article

2 weeks ago • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Using Low-Dose Tirzepatide in Older Adults with Type 2 Diabetes: Treatment Continuation, Blood Sugar Benefits, and Simplified Care in Real LifeClinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults with Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World Cohort.

Article

3 weeks ago • PRiMER (Leawood, Kan.)

Blood Sugar Changes Linked to Shortages of GLP-1 Medicines in Type 2 DiabetesGlycemic Outcomes Associated With GLP-1 Receptor Agonist Shortages in Type 2 Diabetes.

Article

3 weeks ago • Diabetes, obesity & metabolism

GLP-1 Receptor Agonist Treatment Linked to Lower Risk of Foot Amputation in Adults with Type 2 Diabetes and Foot Ulcers Without Diagnosed Artery DiseaseGLP-1 Receptor Agonist Therapy Is Associated With Lower Risk of Lower Extremity Amputation in Adults With Type 2 Diabetes and Foot Ulcer Without Coded Peripheral Arterial Disease: A Hypothesis-Generating Real-World Cohort Study.

Article

3 weeks ago • Diabetes, obesity & metabolism

Effects of GLP-1RA and SGLT2 Inhibitor Treatments on Fat Around the Kidneys in Chronic Kidney Disease PatientsThe Effects of GLP-1RA-Based and SGLT2 Inhibitor Therapy on Perirenal Adipose Tissue in CKD Patients.

Article

3 weeks ago • Annals of medicine and surgery (2012)

Weight-loss drugs that may reduce drinking: using GLP-1 receptor activators as targeted therapy for alcohol use disorderWhen weight-loss drugs reduce drinking: glucagon-like peptide-1 receptor agonists as phenotype-enriched harm-reduction therapy for alcohol use disorder.

Editorial

3 weeks ago • Annals of medicine and surgery (2012)

New drug treatment for obesity: oral semaglutide for weight lossAdvances in pharmacologic management of obesity: oral semaglutide for weight management.

Article

3 weeks ago • JPGN reports

Tirzepatide treatment in teenagers with fatty liver disease linked to metabolism problems: A case seriesTirzepatide use in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD): A case series.

Article

3 weeks ago • Obesity reviews : an official journal of the International Association for the Study of Obesity

Treating Sleep Apnea in Obesity: Using Airway Pressure, Blood Sugar Hormone Therapy, or Both?Rethinking Obstructive Sleep Apnea Care in Obesity: Continuous Positive Airway Pressure, Incretin-Based Therapy, or Both?

Article

← prevpage 15 of 16next →